Company news

Argent Biopharma Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Company Update & Capital Raising

December 21, 2023

Retraction of Statement

December 20, 2023

Pause in trading

December 20, 2023

Share Purchase Plan Closed

August 29, 2023

Pre-clinical Trial Results on CimetrA

August 14, 2023

MGC Pharma Launches Share Purchase Plan

August 1, 2023

MGC receives permission for first import of Psilocybin

July 30, 2023

Commitments Received for GBP 0.7m

July 14, 2023

AMC Places Second Order of ArtemiC for US$1M

July 6, 2023

Malta Production Facility Receives EU-GMP Approval

May 1, 2023

Fundraise closed raising up to a total of GBP 2.09m

April 13, 2023

CannEpil now available by Named Patient Request in UK

April 11, 2023

Funding Commitments Received for GBP 1.8m

April 11, 2023

MGC Receive Permission for Psilocybin Research & Development

April 2, 2023

ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order

March 20, 2023

Completion of CimetrA Mechanism of Action study

March 6, 2023

Provision of US$600,000 Funding and change of CFO

February 3, 2023

Refinancing and Extension to Convertible Security Agreements

February 2, 2023

Results of CimetrA bioanalytics pre-clinal trial

January 9, 2023

Internal Costs Review Completed and Board Change

January 2, 2023

$800,000 of funding received through Mercer Facility

December 23, 2022

Completion of CimetrA Efficacy Pre-clinical Trial

December 7, 2022

US$1,000,000 ArtemiC order delivered to US partner, AMC

December 4, 2022

Publication of Peer Reviewed Glioblastoma Research

December 2, 2022

Long COVID study Results

October 24, 2022

Pause in Trading

October 23, 2022

Operations Update

October 19, 2022

Appointment of UK Corporate Advisor and Company Update

October 4, 2022

TGA advertising Infringement Notice

September 28, 2022

US$550,000 Convertible Note Facility Funding

September 22, 2022

Interim Results - CimetrA Dosing Finding Study

September 20, 2022

US$750,000 Convertible Note Facility Funding

August 24, 2022

AMC Holdings Inc places US$1 million ArtemiC order

August 17, 2022

Study Results - Effects of CannEpil on driving performance

August 15, 2022

US$1.2M Tranche 1 Funding Recevied from Mercer

August 3, 2022

US$10M Financing Agreement signed with US Financier/Investor

July 29, 2022

Strategic Acquisition of 40% interest in ZAM Software Ltd

July 28, 2022

Amended June Quarterly Reports (amended App. 4C)

July 24, 2022

June Quarter Activities and Cash Flow Report

July 24, 2022

Long COVID Study Results for ArtemiC Support

July 14, 2022

Approvals received for South African CimetrA Clinical Trial

July 8, 2022

CimetrA anti-inflammatory pre-clinical study results

June 27, 2022

Glioblastoma pre-clinical trial results

June 16, 2022

Cognicann Clinical Trial Results

June 6, 2022

Response to ASX Aware Query

May 17, 2022

Patent Granted for CannEpiL SNEDDS

May 10, 2022

March 2022 Quarterly Activity and Cash Flow Reports

April 29, 2022

Patent Granted for CimetrA

April 21, 2022

Sciensus Rare EU & UK Sales and Distribution Agreement

April 5, 2022

Response to ASX Query

January 12, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 10 decks. Every deck is listed under its year.